ReviewAmerican journal of nuclear medicine and molecular imaging2015
Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies.
Review in American journal of nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Preclinical Applications of 3'-Deoxy-3'-[Theranostics · 2017Pooled it
- A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.BMC cancer · 2016Trial
- Multimodal radiomics for precision management of colorectal cancer.Discover oncology · 2026Review
- Preclinical PET, PET/CT, and PET/MRI.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Peptide PET Imaging: A Review of Recent Developments and a Look at the Future of Radiometal-Labeled Peptides in Medicine.Chemical & biomedical imaging · 2024Review
- Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC).Molecular cancer research : MCR · 2023Article
- Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects.Journal of nanobiotechnology · 2023Article
- Challenges and opportunities in the development of metal-based anticancer theranostic agents.Bioscience reports · 2022Review
- GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[Molecular imaging and biology · 2022Article
- Imaging Biological Pathways in Abdominal Aortic Aneurysms Using Positron Emission Tomography.Arteriosclerosis, thrombosis, and vascular biology · 2021Review
- Tyrosine Kinase Inhibitors Reduce Glucose Uptake by Binding to an Exofacial Site on hGLUT-1: Influence onClinical and translational science · 2021Article
- [Molecules (Basel, Switzerland) · 2021Article
- Article
- The Distribution Volume ofCancer biotherapy & radiopharmaceuticals · 2019Article
- Evaluation of apoptosis imaging biomarkers in a genetic model of cell death.EJNMMI research · 2019Article
- Radionuclide generators: the prospect of availing PET radiotracers to meet current clinical needs and future research demands.American journal of nuclear medicine and molecular imaging · 2019Review
- Sex as a Biologic Variable in Preclinical Imaging Research: Initial Observations withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Article
- FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study.EJNMMI research · 2017Article
- Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.European journal of nuclear medicine and molecular imaging · 2017Review
- Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT.Journal of visualized experiments : JoVE · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional imaging of solid tumors with positron emission tomography (PET) imaging is an evolving field with continuous development of new PET tracers and discovery of new applications for already implemented PET tracers. During treatment of cancer patients, a general challenge is to measure treatment effect early in a treatment course and by that to stratify patients into responders and non-responders. With 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) and 3'-deoxy-3'-[(18)F]fluorothymidine((18)F-FLT) two of the cancer hallmarks, altered energy metabolism and increased cell proliferation, can be visualized and quantified non-invasively by PET. With (18)F-FDG and (18)F-FLT PET changes in energy metabolism and cell proliferation can thereby be determined after initiation of cancer treatment in both clinical and pre-clinical studies in order to predict, at an early time-point, treatment response. It is hypothesized that decreases in glycolysis and cell proliferation may occur in tumors that are sensitive to the applied cancer therapeutics and that tumors that are resistant to treatment will show unchanged glucose metabolism and cell proliferation. Whether (18)F-FDG and/or (18)F-FLT PET can be used for prediction of treatment response has been analyzed in many studies both following treatment with conventional chemotherapeutic agents but also following treatment with different targeted therapies, e.g. monoclonal antibodies and small molecules inhibitors. The results from these studies have been most variable; in some studies early changes in (18)F-FDG and (18)F-FLT uptake predicted later tumor regression whereas in other studies no change in tracer uptake was observed despite the treatment being effective. The present review gives an overview of pre-clinical studies that have used (18)F-FDG and/or (18)F-FLT PET for response monitoring of cancer therapeutics.
Indexed as
Identifiers
26550536PMC4620172W2419516276What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.